about
A novel enediyne-integrated antibody-drug conjugate shows promising anti-tumor efficacy against CD30+ lymphomas.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.Advances in targeted therapy for acute myeloid leukaemia.Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.Site-Specific Antibody Conjugation for ADC and Beyond.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice.
P2860
Q47217500-2FA028C0-279B-4305-AA45-B8BCD9E48910Q47221234-1B8A2110-0A67-413D-9AEA-12173EFA98D2Q48154329-3C8B43A4-24EF-42D5-9378-2B1A69FB2D2AQ48204144-764FCF93-BCFF-4B6C-8D4F-68A53D280E21Q54956859-6CCF4C20-33E4-4321-A59E-97BD2C5F06A4Q55022669-7780009F-9B75-4C27-B305-F6800B5F388CQ55354182-1BA4924C-4469-4AA9-ACC4-63F2B0F47759Q55385806-FEBB0EDE-9D4F-4C4D-922D-B6ED44D65AC3
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Gemtuzumab ozogamicin in acute myeloid leukemia.
@en
type
label
Gemtuzumab ozogamicin in acute myeloid leukemia.
@en
prefLabel
Gemtuzumab ozogamicin in acute myeloid leukemia.
@en
P2093
P2860
P356
P1433
P1476
Gemtuzumab ozogamicin in acute myeloid leukemia.
@en
P2093
P2860
P2888
P356
10.1038/LEU.2017.187
P577
2017-06-13T00:00:00Z
P6179
1085998915